{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:45:04Z","timestamp":1760550304153},"reference-count":36,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Emerging Microbes & Infections"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/emi.2017.46","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T07:20:56Z","timestamp":1498029656000},"page":"1-7","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions"],"prefix":"10.1080","volume":"6","author":[{"given":"Qianqian","family":"Qi","sequence":"first","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Shanghai Public Health Clinical CenterFudan University, Shanghai 200032, China"},{"name":"Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Shanghai Public Health Clinical CenterFudan University, Shanghai 200032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizao","family":"Chen","sequence":"additional","affiliation":[{"name":"Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[{"name":"Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimiter S","family":"Dimitrov","sequence":"additional","affiliation":[{"name":"Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Lu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Shanghai Public Health Clinical CenterFudan University, Shanghai 200032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Shanghai Public Health Clinical CenterFudan University, Shanghai 200032, China"},{"name":"Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1742-4690-9-104","article-title":"A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains","volume":"9","author":"Lu L","year":"2012","unstructured":"Lu L, Pan C, Li Yet al.A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology 2012;9: 104.","journal-title":"Retrovirology"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1073\/pnas.96.13.7496","article-title":"Constitutive cell surface association between CD4 and CCR5","volume":"96","author":"Xiao X","year":"1999","unstructured":"Xiao X, Wu L, Stantchev TSet al.Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci USA 1999;96: 7496\u20137501.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/nsb1295-1075","article-title":"A trimeric structural domain of the HIV-1 transmembrane glycoprotein","volume":"2","author":"Lu M","year":"1995","unstructured":"Lu M, Blacklow SC, Kim PS.A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2: 1075\u20131082.","journal-title":"Nat Struct Biol"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","article-title":"HIV entry and its inhibition","volume":"93","author":"Chan DC","year":"1998","unstructured":"Chan DC, Kim PS.HIV entry and its inhibition. Cell 1998;93: 681\u2013684.","journal-title":"Cell"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2174\/1381612043384466","article-title":"High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques","volume":"10","author":"Liu S","year":"2004","unstructured":"Liu S, Jiang S.High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Des 2004;10: 1827\u20131843.","journal-title":"Curr Pharm Des"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.virol.2005.06.008","article-title":"Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4","volume":"339","author":"Zhao Q","year":"2005","unstructured":"Zhao Q, Ma L, Jiang Set al.Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005;339: 213\u2013225.","journal-title":"Virology"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1128\/jvi.67.3.1461-1471.1993","article-title":"Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4","volume":"67","author":"Orloff SL","year":"1993","unstructured":"Orloff SL, Kennedy MS, Belperron AAet al.Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J Virol 1993;67: 1461\u20131471.","journal-title":"J Virol"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","first-page":"e1000360","DOI":"10.1371\/journal.ppat.1000360","article-title":"Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state","volume":"5","author":"Haim H","year":"2009","unstructured":"Haim H, Si Z, Madani Net al.Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog 2009;5: e1000360.","journal-title":"PLoS Pathog"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/08820139.2012.736115","article-title":"Role of human CD4 D1D2 domain in HIV-1 infection","volume":"42","author":"Li L","year":"2013","unstructured":"Li L, Shi X, Lu Qet al.Role of human CD4 D1D2 domain in HIV-1 infection. Immunol Invest 2013;42: 106\u2013121.","journal-title":"Immunol Invest"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1128\/JVI.05119-11","article-title":"Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens","volume":"85","author":"Chen W","year":"2011","unstructured":"Chen W, Feng Y, Gong Ret al.Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol 2011;85: 9395\u20139405.","journal-title":"J Virol"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong PD","year":"1998","unstructured":"Kwong PD, Wyatt R, Robinson Jet al.Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393: 648\u2013659.","journal-title":"Nature"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/31514","article-title":"The antigenic structure of the HIV gp120 envelope glycoprotein","volume":"393","author":"Wyatt R","year":"1998","unstructured":"Wyatt R, Kwong PD, Desjardins Eet al.The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393: 705\u2013711.","journal-title":"Nature"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","first-page":"17121","DOI":"10.1073\/pnas.0805297105","article-title":"Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers","volume":"105","author":"Chen W","year":"2008","unstructured":"Chen W, Zhu Z, Feng Yet al.Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008;105: 17121\u201317126.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","first-page":"25154","DOI":"10.1074\/jbc.M113.484154","article-title":"Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics","volume":"288","author":"Ying T","year":"2013","unstructured":"Ying T, Chen W, Feng Yet al.Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem 2013;288: 25154\u201325164.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1128\/JVI.02566-13","article-title":"Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains","volume":"88","author":"Chen W","year":"2014","unstructured":"Chen W, Feng Y, Prabakaran Pet al.Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol 2014;88: 1125\u20131139.","journal-title":"J Virol"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection","volume":"91","author":"Wild CT","year":"1994","unstructured":"Wild CT, Shugars DC, Greenwell TKet al.Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994;91: 9770\u20139774.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"Dwyer JJ","year":"2007","unstructured":"Dwyer JJ, Wilson KL, Davison DKet al.Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 2007;104: 12772\u201312777.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"283","author":"He Y","year":"2008","unstructured":"He Y, Xiao Y, Song Het al.Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008;283: 11126\u201311134.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1021\/bi00859a010","article-title":"Spectroscopic determination of tryptophan and tyrosine in proteins","volume":"6","author":"Edelhoch H","year":"1967","unstructured":"Edelhoch H.Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 1967;6: 1948\u20131954.","journal-title":"Biochemistry"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","first-page":"10785","DOI":"10.1128\/JVI.05331-11","article-title":"Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function","volume":"85","author":"Eggink D","year":"2011","unstructured":"Eggink D, Bontjer I, Langedijk JPet al.Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol 2011;85: 10785\u201310797.","journal-title":"J Virol"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.bbamem.2013.12.022","article-title":"ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer","volume":"1838","author":"Yu F","year":"2014","unstructured":"Yu F, Lu L, Liu Qet al.ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Biochim Biophys Acta 2014;1838: 1296\u20131305.","journal-title":"Biochim Biophys Acta"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2334-1-17","article-title":"Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120","volume":"1","author":"Neurath AR","year":"2001","unstructured":"Neurath AR, Strick N, Li YYet al.Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis 2001;1: 17.","journal-title":"BMC Infect Dis"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1128\/AAC.48.11.4349-4359.2004","article-title":"N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion","volume":"48","author":"Jiang S","year":"2004","unstructured":"Jiang S, Lu H, Liu Set al.N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 2004;48: 4349\u20134359.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou TC","year":"2006","unstructured":"Chou TC.Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58: 621\u2013681.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","first-page":"e1004071","DOI":"10.1371\/journal.ppat.1004071","article-title":"Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing","volume":"10","author":"Wei DG","year":"2014","unstructured":"Wei DG, Chiang V, Fyne Eet al.Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 2014;10: e1004071.","journal-title":"PLoS Pathog"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei X","year":"2002","unstructured":"Wei X, Decker JM, Liu Het al.Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46: 1896\u20131905.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","first-page":"12428","DOI":"10.1128\/JVI.78.22.12428-12437.2004","article-title":"Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor","volume":"78","author":"Baldwin CE","year":"2004","unstructured":"Baldwin CE, Sanders RW, Deng Yet al.Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004;78: 12428\u201312437.","journal-title":"J Virol"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/jac\/dku183","article-title":"The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance","volume":"69","author":"Chong H","year":"2014","unstructured":"Chong H, Yao X, Qiu Zet al.The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance. J Antimicrob Chemother 2014;69: 2759\u20132769.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1084\/jem.176.2.507","article-title":"The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure","volume":"176","author":"Moebius U","year":"1992","unstructured":"Moebius U, Clayton LK, Abraham Set al.The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J Exp Med 1992;176: 507\u2013517.","journal-title":"J Exp Med"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1128\/jvi.69.11.6609-6617.1995","article-title":"Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG","volume":"69","author":"Trkola A","year":"1995","unstructured":"Trkola A, Pomales AB, Yuan Het al.Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69: 6609\u20136617.","journal-title":"J Virol"},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1128\/JVI.77.5.2859-2865.2003","article-title":"Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor","volume":"77","author":"Dey B","year":"2003","unstructured":"Dey B, Del Castillo CS, Berger EA.Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 2003;77: 2859\u20132865.","journal-title":"J Virol"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-4690-7-11","article-title":"sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates","volume":"7","author":"Lagenaur LA","year":"2010","unstructured":"Lagenaur LA, Villarroel VA, Bundoc Vet al.sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 2010;7: 11.","journal-title":"Retrovirology"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1128\/JVI.72.8.6332-6338.1998","article-title":"Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies","volume":"72","author":"Sullivan N","year":"1998","unstructured":"Sullivan N, Sun Y, Binley Jet al.Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol 1998;72: 6332\u20136338.","journal-title":"J Virol"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1128\/JVI.72.3.1876-1885.1998","article-title":"Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage","volume":"72","author":"Trkola A","year":"1998","unstructured":"Trkola A, Ketas T, Kewalramani VNet al.Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 1998;72: 1876\u20131885.","journal-title":"J Virol"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.antiviral.2010.08.004","article-title":"Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates","volume":"88","author":"Chen W","year":"2010","unstructured":"Chen W, Xiao X, Wang Yet al.Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 2010;88: 107\u2013115.","journal-title":"Antiviral Res"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core structure of gp41 from the HIV envelope glycoprotein","volume":"89","author":"Chan DC","year":"1997","unstructured":"Chan DC, Fass D, Berger JMet al.Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89: 263\u2013273.","journal-title":"Cell"}],"container-title":["Emerging Microbes & Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1038\/emi.2017.46","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T12:26:53Z","timestamp":1695385613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1038\/emi.2017.46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1038\/emi.2017.46"],"URL":"https:\/\/doi.org\/10.1038\/emi.2017.46","relation":{},"ISSN":["2222-1751"],"issn-type":[{"value":"2222-1751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=temi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=temi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}